Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:
- Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)
- First-Line Therapy (PD-L1 Negative) (6:53)
- First-Line Therapy (PD-L1 Positive) (23:40)
- Second-Line Therapy (Sequencing) (34:08)
- Adverse Events with TROP2-Targeting ADCs (43:43)